In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $70.62 in the prior trading day, Exact Sciences Corp. (NASDAQ: EXAS) closed at $69.23, down -1.97%. In other words, the price has decreased by -$1.97 from its previous closing price. On the day, 1.32 million shares were traded. EXAS stock price reached its highest trading level at $70.65 during the session, while it also had its lowest trading level at $68.55.
Ratios:
Our goal is to gain a better understanding of EXAS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.98 and its Current Ratio is at 2.17. In the meantime, Its Debt-to-Equity ratio is 0.87 whereas as Long-Term Debt/Eq ratio is at 0.78.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on August 28, 2024, initiated with a Overweight rating and assigned the stock a target price of $75.
On June 27, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $70.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 08 ’24 when Baranick Brian sold 929 shares for $70.00 per share. The transaction valued at 65,030 led to the insider holds 12,758 shares of the business.
Baranick Brian bought 929 shares of EXAS for $65,030 on Oct 08 ’24. On Sep 18 ’24, another insider, Baranick Brian, who serves as the EVP, GM, Precision Oncology of the company, sold 929 shares for $70.00 each. As a result, the insider received 65,030 and left with 13,687 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXAS now has a Market Capitalization of 12791627776 and an Enterprise Value of 14628767744. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.90 while its Price-to-Book (P/B) ratio in mrq is 4.00. Its current Enterprise Value per Revenue stands at 5.601 whereas that against EBITDA is -212.316.
Stock Price History:
Over the past 52 weeks, EXAS has reached a high of $79.62, while it has fallen to a 52-week low of $40.62. The 50-Day Moving Average of the stock is 7.85%, while the 200-Day Moving Average is calculated to be 17.74%.
Shares Statistics:
The stock has traded on average 2.48M shares per day over the past 3-months and 1396930 shares per day over the last 10 days, according to various share statistics. A total of 184.77M shares are outstanding, with a floating share count of 181.98M. Insiders hold about 1.51% of the company’s shares, while institutions hold 97.35% stake in the company. Shares short for EXAS as of 1727654400 were 14031981 with a Short Ratio of 5.66, compared to 1724976000 on 14508256. Therefore, it implies a Short% of Shares Outstanding of 14031981 and a Short% of Float of 7.670000000000001.
